Phase 2 Study of the Assessment of the Insulin Sensitizing Activity of Fenretinide in Subjects With Insulin Resistance With BMI >30Kg/m2, and Liver Inflammation Related to Non-alcoholic Fatty Liver.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Fenretinide (Primary)
- Indications Insulin resistance; Obesity
- Focus Pharmacodynamics
Most Recent Events
- 10 Feb 2021 Biomarkers information updated
- 11 Feb 2013 Planned end date changed from 1 Apr 2011 to 1 Apr 2015 as reported by ClinicalTrials.gov.
- 22 Jul 2010 New trial record